You are viewing: United Kingdom Recombinant Proteins Market analysis
Part of: Recombinant Proteins Market (Global)

The United Kingdom Recombinant Proteins Market was valued at $41.3 Million in 2023 and projected to reach to $62.8 Million by 2028, representing a compound annual growth rate of 8.7%. The United Kingdom recombinant proteins market is positioned for sustained growth, driven by increasing demand for targeted biologics, expanding therapeutic applications, and the country's established expertise in protein engineering.

United Kingdom Recombinant Proteins Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

United Kingdom Recombinant Proteins Market Trends and Insights

  • This growth trajectory reflects the United Kingdom's strengthening position in biopharmaceutical innovation and therapeutic protein development.
  • The United Kingdom's advanced healthcare infrastructure, robust regulatory framework, and significant investment in biotechnology research are driving demand for recombinant protein therapeutics across multiple disease areas. The United Kingdom market is characterized by increasing adoption of recombinant proteins in oncology, immunology, and rare disease treatment.
  • The United Kingdom's pharmaceutical and biotech sectors are leveraging recombinant protein technology to develop novel therapeutics, supported by government initiatives and private sector collaboration.
  • Between 2023 and 2028, the United Kingdom is expected to see accelerated growth driven by rising healthcare expenditure, expanding clinical applications, and growing prevalence of chronic diseases requiring protein-based interventics..

Key Market Statistics

  • CAGR (2023-2028) 8.7% CAGR
  • Market Size, 2023 ~USD 41.3 Million
  • Forecast, 2028 ~USD 62.8 Million
  • Country United Kingdom

United Kingdom Recombinant Proteins Market Overview

Market Valuation Growth :

The UK recombinant proteins market reached $41.3 million in 2023 and is forecast to grow to $62.8 million by 2028, demonstrating robust expansion in the biopharmaceutical sector.

Strong CAGR Performance :

At 8.7% CAGR through 2028, the UK market is outpacing the global average of 7.2%, reflecting the country's competitive advantage in protein therapeutics development.

Regulatory Excellence :

The UK's advanced regulatory framework and post-Brexit autonomy enable faster approval pathways for recombinant protein therapeutics, attracting investment from global biopharmaceutical companies.

Research & Innovation Hub :

The UK hosts world-leading academic institutions and biotech clusters, particularly in Cambridge and London, driving innovation in recombinant protein manufacturing and therapeutic applications.

United Kingdom Recombinant Proteins Market Dynamics

  • The UK's life sciences sector benefits from significant government investment, collaborative research initiatives, and a skilled workforce specializing in biopharmaceutical development. Looking ahead to 2028, the market will be shaped by advances in manufacturing technologies, growing adoption of personalized medicine, and the UK's strategic focus on becoming a global life sciences leader.
  • Continued investment in biotech infrastructure and favorable regulatory conditions are expected to attract both domestic and international players, further accelerating market expansion and innovation in recombinant protein therapeutics..

Market Ecosystem

logo-mobile

RECOMBINANT PROTEINS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Recombinant cytokines and growth factors from its Gibco, Invitrogen, and PeproTech brands are used in cell culture, drug discovery, immunology research, stem cell expansion, and cell therapy manufacturing. Its GMP-grade proteins support the production of cell-based therapies. Supports reproducible cell culture and immune-cell expansion | Enables research-to-manufacturing workflows | Supports clinical manufacturing requirements through GMP-grade proteins.
company logo
Merck provides recombinant protein expression and process-development technologies for biopharmaceutical applications. Its CHOZN expression platform and associated process-development services support the development and scale-up of recombinant proteins and other biologics. Supports high-producing cell-line development | Facilitates process optimization and scale-up | Helps improve manufacturing productivity and consistency.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The United Kingdom recombinant proteins market is valued at $41.3 million in 2023 and will reach $62.8 million by 2028, growing at 8.7% CAGR.
    • The United Kingdom's advanced regulatory environment and biotech infrastructure position it as a key hub for recombinant protein development and commercialization.
    • The United Kingdom market growth is driven by increasing adoption in oncology, immunology, and rare disease therapeutics.
    • The United Kingdom's healthcare system and government support for life sciences innovation are accelerating recombinant protein market expansion through 2028.

    Recombinant Proteins Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment INTERFERONS (IFNS) (Type)
    Forecast Period 2023-2028
    Growth Rate CAGR of 7.2% from 2023 to 2028
    Largest Segment PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User)
    Market Size Base Year (Billions) ~USD 2.26 (2023)
    Revenue Forecast (Billions) ~USD 3.2 (2028)
    Segments Covered Product, Type, Application, Host Cell, End User

    United Kingdom Recombinant Proteins Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product

    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Other Recombinant Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins

    By Type

    • Academic Research
    • Biologics
    • Biotechnology Research
    • Cell & Gene Therapy
    • Interferons (Ifns)
    • Interleukins (Ils)
    • Other Growth Factors & Chemokines
    • Vaccines

    By Application

    • Biopharmaceutical Production
    • Diagnostics
    • Drug Discovery & Development
    • Other Applications
    • Research

    By Host Cell

    • Bacterial Cells
    • Insect Cells
    • Mammalian Systems
    • Other Cell Hosts
    • Other Host Cells
    • Yeast & Fungi

    By End User

    • Academic Research Institutes
    • Biotechnology Companies
    • Contract Research Organizations
    • Other End Users
    • Pharmaceutical & Biopharmaceutical Companies

    Target Audience

    • Biopharmaceutical Companies : UK and international pharma firms need detailed market data to assess expansion opportunities, optimize R&D investments, and develop targeted commercialization strategies for the UK recombinant proteins market.
    • Biotech Startups & SMEs : Emerging UK biotech companies require market intelligence to validate business models, secure funding, identify partnership opportunities, and position products within the competitive UK landscape.
    • Healthcare Investors & VCs : Investment firms evaluating UK life sciences opportunities need comprehensive market analysis to assess growth potential, identify promising companies, and make informed capital allocation decisions.
    • Contract Research Organizations : CROs and manufacturing partners need UK market forecasts to anticipate demand for services, plan capacity expansion, and develop service offerings aligned with market growth trajectories.
    • Healthcare Policy & Government Bodies : UK government agencies and NHS organizations require market data to inform life sciences strategy, allocate healthcare budgets, and support policy decisions affecting the recombinant proteins sector.

    Reasons to Buy this Report

    • UK-Specific Market Sizing : Obtain precise valuation data for the United Kingdom market ($41.3M in 2023) with detailed forecasts through 2028, enabling accurate budget allocation and investment planning for UK operations.
    • Competitive Landscape Intelligence : Understand the UK's unique competitive positioning with 8.7% CAGR outperforming global averages, identifying opportunities to capitalize on the country's regulatory advantages and innovation ecosystem.
    • Regulatory & Policy Insights : Gain clarity on UK-specific regulatory pathways, post-Brexit approval processes, and government support mechanisms that directly impact market entry strategies and commercialization timelines.
    • Investment & Partnership Opportunities : Identify high-growth segments and key stakeholders within the UK biotech cluster, including academic institutions, CROs, and manufacturers, to inform partnership and acquisition strategies.
    • Strategic Market Planning : Develop evidence-based go-to-market strategies tailored to the UK healthcare system, NHS procurement processes, and regional demand drivers for recombinant protein products.

    Frequently asked questions

    What is the current size of the United Kingdom recombinant proteins market?

    The United Kingdom recombinant proteins market was valued at $41.3 million in 2023 and is expected to grow to $62.8 million by 2028.

    What is the projected growth rate for the United Kingdom recombinant proteins market?

    The United Kingdom recombinant proteins market is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2028.

    Which therapeutic areas are driving growth in the United Kingdom recombinant proteins market?

    The United Kingdom market is experiencing strong growth in oncology, immunology, and rare disease treatment segments, supported by increasing clinical adoption and healthcare investment.

    What factors are supporting recombinant protein market expansion in the United Kingdom?

    The United Kingdom's advanced healthcare infrastructure, robust regulatory framework, government life sciences initiatives, and strong biotech sector are key drivers of market growth.

    How does the United Kingdom recombinant proteins market compare to other European markets?

    The United Kingdom's 8.7% CAGR reflects strong market fundamentals and positions the country as a significant player in European recombinant protein development and commercialization.

    RESEARCH METHODOLOGY

    This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global recombinant proteins market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.

    Secondary Research

    The secondary sources referred to for this research study include publications from government sources,such as the World Health Organization, The Antibody Society,Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC),National Center for Biotechnology Information (NCBI), American Medical Association (AMA), RecombinantAntibody Network (RAN), National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), and the Institute for Molecular Medicine, corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, professional associations, and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

    Recombinant Protein Market 
 Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The top-down and bottom-up approaches were used to estimate & validate the total size of the recombinant proteins market. These methods were also used extensively to estimate the size of various market segments.

    Recombinant Protein Market Top Down and Bottom Up Approach

    Data Triangulation

    After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.

    Market Definition

    Recombinant proteins are manipulated proteins generated by recombinant DNA technology that modifies gene sequences. These are formed by transfecting foreign genes into a host cell. Recombinant proteins are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses. This market includes recombinant protein products, including growth factors, cytokines, recombinant enzymes, structural proteins, and membrane proteins.

    Key Stakeholders

    • Pharmaceutical & Biopharmaceutical Companies
    • Biotechnology Companies
    • Life Sciences Companies
    • Academic Research Institutes
    • Government Institutes
    • Private Research Firms
    • Contract Research Organizations (CROs)
    • Third-party Suppliers, Direct Suppliers, Distributors, and Channel Partners
    • Venture Capitalists and Investors
    • Market Research and Consulting Firms

    Report Objectives

    • To define, describe, and forecast the recombinant proteins market based on product, host cell, application, and end user
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall recombinant proteins market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders  
    • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To strategically profile the key players in the recombinant proteins market and comprehensively analyze their core competencies and market rankings
    • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the recombinant proteins market
    • To benchmark players within the recombinant proteins market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe recombinant proteins market, by country
    • Further breakdown of the Rest of Asia Pacific recombinant proteins market, by country
    • Further breakdown of the Rest of Latin America recombinant proteins market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

     

    Get the Full Recombinant Proteins Market Report

    Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status